AZD4547: Phase Ib/IIa started

Cancer Research UK (London, U.K) began a dose-finding, U.K. Phase Ib/IIa trial to evaluate AstraZeneca's AZD4547 plus cisplatin and capecitabine. The Phase Ib portion of the trial will enroll about 18 patients with solid tumors who will receive twice-daily AZD4547 and twice-daily capecitabine for the first 2 weeks of a 3-week cycle plus IV cisplatin once per cycle. The second part of the trial will enroll stomach and esophageal cancer patients expressing a high amount of FGFR2, and compare AZD4547 plus capecitabine and cisplatin vs. capecitabine and cisplatin alone. Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland) markets Xeloda capecitabine. ...